This independent CME/CE activity is supported by educational grants from

Bristol-Myers Squibb and ImClone Systems a wholly owned subsidiary of Eli Lilly and Company

Genentech BioOncology

Sanofi-Aventis U.S.

The Certificate Program in
Advanced/Metastatic Colorectal Cancer
  1. Course List

Currently Available

Course Title Faculty Release Date
Expert Insight Into: Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit from an anti-EGFR Monoclonal Antibody in Wild-Type KRAS Metastatic Colon Cancer—Article Review (CC01.16) 1912.12 Saltz Mar 2010
Expert Insight Into: Treatment with an Anti-VEGF Monoclonal Antibody Beyond First Progression is Associated with Prolonged Overall Survival in Metastatic Colorectal Cancer: Results from a Large Observational Cohort Study (BRiTE)—Article Review (CC01.15) 1912.11 Eng Mar 2010
Expert Insight Into: Physical Activity and Male Colorectal Cancer Survival—Article Review (CC01.14) 1912.10 Eng Feb 2010
Case Study: Incurable Metastatic Colorectal Cancer—Tx Reporter e-Newsletter (CC01.13) 1913.04 Saltz Jan 2010
Expert Insight Into: Preoperative Radiotherapy Versus Selective Postoperative Chemoradiotherapy in Patients with Rectal Cancer (MRC CR07 and NCIC-CTG C016): A Multicentre, Randomised Trial—Article Review (CC01.12) 1912.09 Sigurdson Jan 2010
Expert Insight Into:
Microsatellite Instability and Response to Adjuvant Therapy in Patients with Stage III Colon Cancer—Article Review (CC01.11) 1912.08		 Meyerhardt Dec 2009
Case Study: Locally Advanced (T3N0) Rectal Cancer—Tx Reporter e-Newsletter (CC01.10) 1913.03 Saltz
Sigurdson		 Nov 2009
Expert Insight Into: Outcome of Primary Tumor in Patients with Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery as Initial Treatment—Article Review (CC01.09) 1912.07 Meyerhardt Nov 2009
Expert Insight Into: Patients with Initially Unresectable Colorectal Liver Metastases: Is There a Possibility of Cure?—Article Review (CC01.08) 1912.06 Sigurdson Oct 2009
Case Study: Stage IV Colon Cancer with Potential for Conversion to Resectability—Tx Reporter e-Newsletter (CC01.07) 1913.02 Meyerhardt Sep 2009
Expert Insight Into: Perioperative Chemotherapy and Surgery Versus Surgery Alone for Resectable Liver Metastases in Patients with Colorectal Cancer —Article Review (CC01.06) 1912.05 Sigurdson Sep 2009
Expert Insight Into: Dangers of Chemotherapy Plus Concurrent Anti-EGFR and Anti-VEGF Antibodies in Metastatic Colorectal Cancer—Article Review (CC01.05) 1912.04 Saltz Aug 2009
Expert Insight Into: Anti-VEGF plus Oxaliplatin-Based Chemotherapy as First-Line Treatment for Metastatic Colorectal Cancer: A Randomized Phase III Study—Article Review (CC01.04) 1912.03 Eng Jul 2009
Case Study: Postoperative Management of High-Risk Stage II Colon Cancer—Tx Reporter e-Newsletter (CC01.03) 1913.01 Eng
Saltz		 Jul 2009
Expert Insight Into: A New Chemotherapy + Targeted Agent Regimen as Initial Treatment for Metastatic Colorectal Cancer—Article Review (CC01.02) 1912.02 Meyerhardt Jul 2009
Expert Insight Into: Relationship Between K-ras Mutation Status and Benefit of Anti-EGFR Antibodies in Advanced Colorectal Cancer —Article Review (CC01.01) 1912.01 Saltz May 2009